Screener
Sionna Therapeutics SION CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Sionna Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033876
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating lease liabilities | (543) | (528) |
| Net cash used in operating activities | (21,840) | (16,288) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | — | (86) |
| Purchases of marketable securities | (25,327) | (171,595) |
| Maturities of marketable securities | 50,147 | 30,487 |
| Net cash provided by (used in) investing activities | 24,820 | (141,194) |
| Cash flows from financing activities: |
Item 1. Financial Statements
FAQ
- What is Sionna Therapeutics's capex?
- Sionna Therapeutics (SION) reported capex of $0 in Q1 2026.
- How has Sionna Therapeutics's capex changed year-over-year?
- Sionna Therapeutics's capex decreased by 100.0% year-over-year, from $86K to $0.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Sionna Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude